Treat addiction with psychedelics? — Harvard Gazette
Despite promise of success stories from patients in recovery, Law School panel cautions that research is lacking on benefits vs. risks.
Despite promise of success stories from patients in recovery, Law School panel cautions that research is lacking on benefits vs. risks.
Differences in pace of hemodynamic change signal need for sex-specific management
Daniel Su, MD describes the promise of APX3330 for delaying or preventing diabetic retinopathy progression in a post-hoc analysis of the ZETA-1 trial.
Indian generic drugmaker Alembic Pharma reported a 17% rise in fourth-quarter profit on Thursday, driven by strong sales, especially in the key North American market.
MHR is pleased to announce our Early Career Innovator Series, and invites early career scientists, who are within ten years of starting an independent position,
Background The results of high-throughput biology (‘omic’) experiments provide insight into biological mechanisms but can be challenging to explore, archive and share. The scale of…
There were 1,300 cases of the bacterial infection in March, after just over 900 in February in England.
Objectives We aimed to use a large dataset to compare self-reported and primary care measures of insomnia symptom prevalence in England and establish whether they…
The spread of bird flu in mammals with which humans have close contact has unsettled many scientists. “That’s a different ball game altogether,” one said.
We’ve just passed 100 days since the first participant in our clinical trial received his Neuralink implant. Read our latest progress update.
A new assessment tool that leverages powerful artificial intelligence was able to predict whether participants exhibited suicidal thoughts and behaviors using a quick and simple…